Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

The study was a case-control study. We started the study to be performed on eighty subjects divided into four groups:

The first group: include twenty subjects with type 2 diabetes mellitus The second group: include twenty obese subjects whose body mass index is 30 or over The third group: include twenty obese subjects with type 2 diabetes mellitus The fourth group includes twenty apparently healthy subjects as control.

In this study, we concluded that:

• Serum fetuin-A can be used as a biomarker and independent risk factor and marker for diagnosis of DM and DM has a detrimental effect on serum fetuin-A fetuin-A could be of relevance for the development of insulin resistance
• Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance
• Increased serum fetuin-A levels constitute an independent marker of lipid profile.
• fetuin-A may play a role in the pathogenesis of T2DM.
• The inhibition of insulin receptor by fetuin-A may lead to increased lipolysis and efflux of free fatty acids from adipose tissue. This could explain associated dyslipidemia observed in type 2 diabetic patients in the present study.

Finally, our finding that high plasma fetuin-A levels predict the incidence of type 2 diabetes independently of other established risk factors supports the hypothesis that fetuin-A may play a role in the development of type 2 diabetes.

Inclusion criteria

• • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Exclusion criteria

• • Cardiac disease and Hypertensive disease

• Respiratory disease
• Renal disease
• GIT and Liver disease
• Rheumatologic disease
• Blood disease
• Endocrine disease except for type 2 diabetes mellitus
• All with a specific therapeutic drug history.